First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Furtado, M. V. [1 ]
Rule, S. [1 ]
机构：
[1] Derriford Hosp, Dept Haematol, Plymouth PL6 8DH, Devon, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
119
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [41] A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
    Evens, Andrew M.
    Vose, Julie M.
    Harb, Wael
    Gordon, Leo I.
    Langdon, Robert
    Grant, Barbara
    Sprague, Julian
    Plasencia, Clara
    Sirisawad, Mint
    Yue, Jeanne
    Luan, Ying
    Siek, Aaron
    Thou, Lei
    Balasubramanian, Sriram
    Bartlett, Nancy L.
    BLOOD, 2012, 120 (21)
  • [42] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [43] Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)
    Vij, Ravi
    Chang, Betty Y.
    Berdeja, Jesus G.
    Huff, Carol Ann
    Lendvai, Nikoletta
    Tai, Yu-Tzu
    Chang, Stella
    Moussa, Davina
    Buggy, Joseph J.
    Elias, Laurence
    Richardson, Paul G.
    BLOOD, 2012, 120 (21)
  • [44] Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
    Carlo Visco
    Alice Di Rocco
    Andrea Evangelista
    Francesca Maria Quaglia
    Maria Chiara Tisi
    Lucia Morello
    Vittorio Ruggero Zilioli
    Chiara Rusconi
    Stefan Hohaus
    Roberta Sciarra
    Alessandro Re
    Cristina Tecchio
    Annalisa Chiappella
    Ana Marin-Niebla
    Rory McCulloch
    Guido Gini
    Tommasina Perrone
    Luca Nassi
    Elsa Pennese
    Piero Maria Stefani
    Maria Christina Cox
    Valentina Bozzoli
    Alberto Fabbri
    Valentina Polli
    Simone Ferrero
    Maria Isabel Alvarez De Celis
    Antonello Sica
    Luca Petrucci
    Luca Arcaini
    Simon Rule
    Mauro Krampera
    Umberto Vitolo
    Monica Balzarotti
    Leukemia, 2021, 35 : 932 - 932
  • [45] The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib (vol 161, pg 43, 2013)
    Dasmahapatra, G.
    Patel, H.
    Dent, P.
    Fisher, R., I
    Friedberg, J.
    Grant, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (05) : 884 - 886
  • [46] New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor
    Rousseau, Adrien
    Thieblemont, Catherine
    BULLETIN DU CANCER, 2021, 108 (02) : 142 - 144
  • [47] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
    Baggio, Diva
    Wellard, Cameron
    Chung, Eliza
    Talaulikar, Dipti
    Keane, Colm
    Opat, Stephen
    Giri, Pratyush
    Minson, Adrian
    Cheah, Chan Yoon
    Armytage, Tasman
    Lee, Denise
    Chong, Geoffrey
    Johnston, Anna
    Cochrane, Tara
    Waters, Neil
    Hamad, Nada
    Wood, Erica M.
    Hawkes, Eliza A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
  • [48] Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience
    de la Fuente, Adolfo
    Gonzalez, Gloria
    Garcia-Carbonero, Iciar
    Garcia-Frade, Javier
    Munarriz, Javier
    Aguiar, David
    Cuevas, Beatriz
    Cuevas, Maria Victoria
    Aporta, Rafael
    Barez, Abelardo
    Callejas, Marta
    Murias, Adolfo
    Altes, Albert
    Salar, Antonio
    Sanchez-Gonzalez, Blanca
    Grande, Carlos
    Garcia-Marco, Jose A.
    Lopez, Angeles
    Moran, Marina
    Viqueira, Andrea
    Briones, Javier
    BLOOD, 2013, 122 (21)
  • [49] Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience
    Le Gouill, S.
    Kroeger, N.
    Dhedin, N.
    Nagler, A.
    Bouabdallah, K.
    Yakoub-Agha, I.
    Kanouni, T.
    Bulabois, C. E.
    Tournilhac, O.
    Buzyn, A.
    Rio, B.
    Moles, M. P.
    Shimoni, A.
    Bacher, U.
    Ocheni, S.
    Milpied, N.
    Harousseau, J. L.
    Moreau, P.
    Leux, C.
    Mohty, M.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2695 - 2703
  • [50] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi Luigi
    BLOOD, 2021, 138
12345